First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects
Author:
Affiliation:
1. Pfizer Inc Cambridge Massachusetts
2. Pfizer Inc New Haven Connecticut
3. Pfizer Inc Collegeville Pennsylvania
4. Pfizer Inc Andover Massachusetts
Funder
Pfizer
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14187
Reference43 articles.
1. Biomarkers of Inflammatory Bowel Disease
2. Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010
3. Immunopathology of inflammatory bowel disease
4. Expression, Localization, and Functional Activity of TL1A, a Novel Th1-Polarizing Cytokine in Inflammatory Bowel Disease
5. TL1A as a Potential Local Inducer of IL17A Expression in Colon Mucosa of Inflammatory Bowel Disease Patients
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD;Gut;2024-09-11
2. Progress in research of TNF-like cytokine 1A as a therapeutic target for inflammatory bowel disease;World Chinese Journal of Digestology;2024-06-28
3. TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis;Med;2024-05
4. Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development;Drug Discovery Today;2024-05
5. The ever-expanding role of cytokine receptor DR3 in T cells;Cytokine;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3